Aydah AlAwadhi, Board Member at The Arab Board of Health Specializations, shared on LinkedIn:
“Are we overtreating early HR+positive / HER2-negative breast cancer with chemotherapy?
A thought-provoking perspective in Journal of Clinical Oncology revisits four landmark trials: MINDACT – TAILORx – RxPONDER – OPTIMA.
A fascinating evolution in how genomic-guided decision-making is reshaping chemotherapy use in HR+/HER2− early breast cancer, moving us closer to the right treatment for the right patient.”
Title: From TAILORx to OPTIMA: Evolving Evidence for Genomically Guided Chemotherapy in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Authors: Yara Abdou, Lisa A. Carey.
Read the full article.
You might be interested in:
- OPTIMA: Prosigna-Guided Chemotherapy Avoidance Shows Non-Inferior Outcomes in ER+/HER2− Early Breast Cancer
- SABCS 2026: The Top 10 Breast Cancer Studies to Watch for Potential Practice-Changing Results
